Highlights: Final three subjects in cohort three have been intravenously dosed; RECCE® 327 at 500mg indicating to be safe and...
Results Distinguish Deep TMS as More Effective in Subjects with Higher Anxiety Symptoms, Long Considered Less Responsive to Alternative TreatmentsBURLINGTON,...
MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader...
- Preclinical data demonstrates new RaniPill™ HC (High Capacity) delivered 500%-plus higher payloads than current RaniPill™ capsule - - Up...
State-of-the-art GMP manufacturing facility to support preclinical through commercial production of Intellia’s investigational therapiesNew facility in Waltham, Massachusetts expected to...
Interim Results expected mid-2022REHOVOT, Israel and WILMINGTON, Del., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a...
VANCOUVER, British Columbia,, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Simply Better Brands Corp. (the “Company” or “Simply Better Brands” or...
Staffed by a Highly Experienced Team of Licensed Hearing Professionals and Leading Salespeople from Competitor PlatformsAims to Enhance Customer Experience...
RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial...
Vystar/Rotmans would have singular focus on furniture/bedding industry to be attractive reverse merger opportunityRxAir NewCo would include RxAir®, Vytex® and...
BANNOCKBURN, Ill., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH),...
Pivotal Trial to Assess the Potential of Aficamten to Improve Exercise Capacity, Heart Failure Symptoms and Functional ClassSOUTH SAN FRANCISCO,...
KemPharm Positioned to Submit IND Application for KP1077 for Idiopathic Hypersomnia by Mid-2022 CELEBRATION, Fla., Feb. 23, 2022 (GLOBE NEWSWIRE)...
Amryt to Report FY and Q4 2021 Results on March 9, 2022 DUBLIN, Ireland, and Boston MA, February 23, 2022,...
SOMERVILLE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage...
– FYARRO™ added to NCCN® Guidelines as the only preferred mTOR inhibitor to treat malignant PEComa –– PRECISION-1 tumor agnostic...
VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB:...
— Q4 2021 ORLADEYO net revenue of $46.2 million and $122.6 million for FY 2021 — — ORLADEYO net revenue...
BOCA RATON, Fla., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF),...
Full Scope of New Service Capabilities to be Operational in Q2; Company Has Already Secured Project Commitments from Multiple New...